Alan Maynard, a professor of health economics, argued drug firms were demanding much higher prices than were reasonable, and the economies were justified.
"Nice are looking for good evidence and the industry is rather poor in doing good trials and telling us about the full effectiveness - which is often marginal," he said.
"I think it's quite inevitable that in a period of austerity there will be downward pressure on the introduction of new drugs that are not demonstrably good in terms of improving patient health and which are extraordinarily expensive."
Saturday, February 25, 2012
BBC News - Cancer drug delays - Maynard speaks